MetLife SEC Filings

MetLife, Inc. (MET) has filed a Form 144 with the U.S. Securities and Exchange Commission disclosing a planned sale of 27 shares of its common stock. The shares, carrying an aggregate market value of $2,120.85, are slated for sale on or about 20 June 2025 through Barclays Capital, 745 Seventh Ave, New York, NY 10019. The notice cites 671,297,826 shares outstanding, making the proposed transaction an immaterial fraction of total equity.

The filer also reported prior dispositions over the past three months totaling 686 shares for gross proceeds of roughly $55,392, executed on 21 March 2025 and 13 June 2025 by various MetLife-related accounts. The signing party affirms that no undisclosed material adverse information exists and that Rule 10b5-1 representations are satisfied.

MetLife, Inc. (MET) filed a Form 144 with the SEC disclosing a proposed sale of 360 common shares through Barclays Capital on or after 20 June 2025. The shares have an aggregate market value of $28,278, compared with the company’s 671,297,826 shares outstanding, representing less than 0.0001 % of total equity—an immaterial amount from an ownership-dilution perspective.

The filer originally acquired the shares on 29 May 2015 via a purchase from Goldman Sachs for cash. The notice affirms the seller’s representation that no undisclosed material adverse information is known.

Recent trading history: in the last three months, related MetLife accounts collectively sold 686 shares for $55,391.75 in gross proceeds. These transactions, combined with the planned 360-share disposition, remain de minimis relative to MetLife’s market capitalization and average daily trading volume. No financial performance data, strategic updates or governance changes accompany the filing.

Given the modest size and routine nature of the transaction, the filing is unlikely to influence MetLife’s valuation or trading dynamics.

MetLife, Inc. (MET) – Form 144 filing: The notice discloses a proposed sale of 101 common shares with an aggregate market value of $7,933.55. The shares were originally purchased on 12/17/2019 for cash and are slated to be sold through Barclays Capital on or about 06/20/2025 on the NYSE. The issuer has 671,297,826 shares outstanding, so the planned transaction represents less than 0.00002 % of equity. The filing also lists earlier sales by related MetLife accounts over the past three months totaling 686 shares for gross proceeds of $55,391.75. The signer affirms no undisclosed material adverse information and Rule 144 compliance.

MetLife Director Robert Glenn Hubbard acquired 964 shares of common stock on June 17, 2025, at a price of $77.85 per share, bringing his total direct beneficial ownership to 100,489 shares.

The acquisition was part of MetLife's non-management director compensation arrangements, where a portion of director retainer fees is paid in company common stock. Hubbard elected to defer the receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

Key transaction details:

• Transaction type: Acquisition of non-derivative securities
• Total value of transaction: Approximately $75,047 (964 shares × $77.85)
• Ownership form: Direct
• Filing made as an individual reporting person

MetLife Director Jeh C. Johnson reported the acquisition of 562 shares of common stock at $77.85 per share on June 17, 2025, bringing total direct ownership to 6,789 shares.

The transaction was part of MetLife's non-management director compensation arrangement, where a portion of director retainer fees is paid in company stock. Johnson elected to defer the receipt of these shares through the MetLife Deferred Compensation Plan for Non-Management Directors.

• Transaction Type: Acquisition (Code A)
• Form Type: Form 4 (Statement of Changes in Beneficial Ownership)
• Transaction Value: Approximately $43,752
• Ownership: Direct

This routine compensation-related transaction demonstrates continued alignment between director and shareholder interests through equity-based compensation.

MetLife director Denise M. Morrison reported the acquisition of 562 shares of common stock on June 17, 2025 as part of the company's non-management director compensation arrangements. The shares were acquired at $0 cost as part of director retainer fees paid in company stock.

Following this transaction, Morrison now beneficially owns a total of 32,817 shares directly. The filing indicates this is a routine compensation-related acquisition for board service rather than an open market purchase.

• Transaction Type: Stock Award (Compensation)
• Form of Ownership: Direct
• Role: Non-Management Director
• No derivative securities were involved in this transaction

MetLife director Christian Stephane Mumenthaler acquired 562 shares of common stock on June 17, 2025 at a price of $77.85 per share, bringing total direct ownership to 918 shares.

The transaction was part of MetLife's non-management director compensation arrangement, where a portion of director retainer fees is paid in company stock. Notably, Mumenthaler elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

• Transaction Type: Acquisition (Form 4)
• Total Transaction Value: $43,751.70
• Ownership Type: Direct
• Role: Non-Management Director

Form 4 overview – MetLife, Inc. (MET)

Director Mark A. Weinberger reported a routine equity award on 17 Jun 2025. He received 562 shares of MetLife common stock at a stated price of $0, reflecting the company’s practice of paying a portion of non-management director retainers in shares. Following the transaction, Weinberger’s direct ownership increased to 16,907 shares.

No derivative securities were involved and the filing contains no additional purchases, sales or option exercises. The award appears to be automatic, formula-based compensation and does not signal discretionary buying or selling by the director.

MetLife, Inc. (NYSE: MET) – Form 4 insider transaction filed 20 Jun 2025

Non-management director Diana McKenzie reported the acquisition of 562 shares of MetLife common stock on 17 Jun 2025 at a reference price of $77.85 per share. The transaction was coded “A(1),” indicating the shares were issued as part of the company’s non-management director compensation plan rather than an open-market purchase. After the grant, McKenzie’s direct beneficial ownership rose to 22,065 shares.

The filing notes that the director elected to defer receipt of the shares under the MetLife Deferred Compensation Plan for Non-Management Directors. No derivative securities were reported, and there were no dispositions.

While the amount is immaterial relative to MetLife’s ~805 million shares outstanding, routine equity compensation aligns director incentives with shareholder returns and remains a data point for governance and insider-sentiment trackers.